Leukotriene Receptor Antagonist

Leukotriene Receptor Antagonists (70):

Cat. No.	Product Name	Effect	Purity

HY-133159

Resolvin E2	Antagonist	98.5%
Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E₂, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.

HY-108396

γ-Linolenic acid ethyl ester	Antagonist	99.14%
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist.

HY-182515

U-19052	Antagonist
U-19052 is a selective competitive peptidoleukotriene D/E receptor antagonist. U-19052 acts as a reversible antagonist that not affecting responses to non-leukotriene agonists. U-19052 does not exhibit agonist activity or induce contraction in guinea pig tracheal or ileal strips. U-19052 is a leukotriene antagonist developed by modifying leukotriene chemical structure. U-19052 can be used for the research of allergic asthma and hypersensitivity diseases.

HY-113727

SC-39070	Antagonist
SC-39070 is a LTD4 receptor antagonist. SC-39070 blocks the contractile effect of LTD4 on guinea pig trachea.

HY-106929

Moxilubant	Antagonist	99.83%
Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease.

HY-111212

Tomelukast	Antagonist	99.0%
Tomelukast (LY171883) is an orally active leukotriene D₄ and E₄ antagonist. Tomelukast can be used for the research of asthma.

HY-B0290R

Pranlukast (Standard)	Antagonist
Pranlukast (Standard) is the analytical standard of Pranlukast. This product is intended for research and analytical applications. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [³H]LTE₄, [³H]LTD₄, and [³H]LTC₄ bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe	Antagonist	98.10%
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology.

HY-116326

BayCysLT2	Antagonist
BayCysLT2, an isophthalic acid derivative, is a selective and potent cysteinyl leukotriene 2 (CysLT2) receptor antagonist with an IC₅₀ value of 53 nM. BayCysLT2 inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. BayCysLT2 reverses LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts.

HY-156978

Ritolukast	Antagonist	99.92%
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD₄/E₄) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD₄ in guinea pigs, with an ID₅₀ of 0.5mg/kg.

HY-101676

RG-12525	Antagonist	98.31%
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC₅₀s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC₅₀ of appr 60 nM and a potent inhibitor of CYP3A4, with a K_i value of 0.5 µM.

HY-13315S1

Montelukast-d₆ sodium	Antagonist
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage.

HY-107610

SR2640 hydrochloride	Antagonist	99.41%
SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma.

HY-112532

REV 5901	Antagonist	99.9%
REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a K_i of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma.

HY-107607

FPL-55712 free base	Antagonist	98.0%
FPL-55712 free base is a leukotriene receptor antagonist. FPL-55712 free base is also an antagonist of slow reacting substance of anaphylaxis (SRS-A). FPL-55712 free base inhibits leukotriene-induced bronchoconstriction.

HY-106785

Pobilukast	Antagonist	99.84%
Pobilukast is a classical CysLT1 receptor antagonist. Pobilukast can be used for the research of asthma.

HY-17492R

Zafirlukast (Standard)	Antagonist
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-13315AR

Montelukast (Standard)	Antagonist
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT₁). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research.

HY-145234

GPBAR1-IN-3	Antagonist
GPBAR1-IN-3 (Compound 14) is a selective GPBAR1 agonist (EC₅₀=0.17 μM) and a CysLT₁R antagonist.

HY-105221

Masilukast	Antagonist	99.60%
Masilukast is an orally administered cysteinyl leukotriene D₄ (LTD₄) receptor antagonist with potential to research asthma.

Name
Email *

	Sorry, but the email address you supplied was invalid.